None
EN
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
[]
Kingston This Week
Advertisement 2 Story continues below This advertisement has not loaded yet, but your article continues below.
Please try againArticle contentAdvertisement 3 Story continues below This advertisement has not loaded yet, but your article continues below.
Article content For NeOnc, the headline is straightforward: NEO100 substantially exceeded its historical Phase 2a benchmark, delivered statistically significant results, and now advances toward its next regulatory step.
Advertisement 4 Story continues below This advertisement has not loaded yet, but your article continues below.
Cautionary Note Regarding Forward-Looking StatementsAdvertisement 5 Story continues below This advertisement has not loaded yet, but your article continues below.